Articles related to GENITOURINARY CANCER

In this cohort analysis, which included male patients examined at 128 US Veterans Health Administration facilities between 2005 (n = 4,678,412) and 2019 (n = 5,371,701), facilities with greater rates of prostate-specific antigen screening showed lower rates of eventual metastatic prostate cancer incidence.

Radiation field size and the effects of ADT sequencing for various oncologic end goals interact significantly. Concurrent/adjuvant ADT was linked to considerably better metastasis-free survival, prostate cancer-specific mortality, and overall survival with prostate-only radiation; the impact of ADT sequencing with whole-pelvic radiation is less clear, with neither consistently showing a benefit.

Cediranib plus olaparib improved rPFS in men with mCRPC compared to olaparib alone. This combination was linked to an increase in the occurrence of grade 3-4 adverse events. BRCA2-mutated subgroups receiving olaparib with or without cediranib had a numerically longer median rPFS.

The researchers believe these are the first data to compare FGFR-directed therapy with chemotherapy in patients with FGFR-altered UC, demonstrating comparable efficacy and manageable safety. Experimentation revealed that FGFR3 DNA alterations in conjunction with FGFR1/3 mRNA overexpression may be better predictors of rogaratinib response.

Cancer Therapy Advisor provides a variety of resources, including regimens used to supplement the most recent treatment strategies. Examine all regimens here.

A multi-variate analysis published in Cancer Medicine, which includes a population of more than 150,000 individuals, suggests that prior cannabis use was associated with a reduced risk of renal cell carcinoma and bladder cancer in women and prostate cancer in men. A potentially conflicting finding was increased risk of some cancers in current cannabis users.